NCT01777542View on ClinicalTrials.gov

Treatment of Rett Syndrome With Recombinant Human IGF-1

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

July 31, 2016

Study Completion Date

November 30, 2016

Conditions
Rett Syndrome
Interventions
DRUG

Recombinant Human Insulin Growth Factor 1 (rhIGF-1)

Subjects will receive twice daily subcutaneous injections of IGF-1.

DRUG

Placebo

Subjects will receive twice daily subcutaneous injections of a saline solution (placebo).

Trial Locations (1)

02215

Boston Children's Hospital, Boston

All Listed Sponsors
collaborator

International Rett Syndrome Foundation

OTHER

lead

Boston Children's Hospital

OTHER

NCT01777542 - Treatment of Rett Syndrome With Recombinant Human IGF-1 | Biotech Hunter | Biotech Hunter